Leukemia

Most patients with cancer demonstrated antibody responses to COVID-19 vaccination after two doses of the mRNA-1273 vaccine, according to an observational study published in JAMA Oncology.

The FDA placed a partial clinical hold on a phase 1 dose-escalation study of a therapy under investigation for certain patients with blood cancer.

One of the major complaints of clinicians who treat patients with chimeric antigen receptor T-cell therapies is the time required to produce the highly individualized treatment.

Survivors of adolescent and young-adult acute myeloid leukemia and acute lymphoblastic leukemia had lower long-term survival rates than the general population, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.

Philip D. Greenberg, MD, FAACR, has been elected American Association for Cancer Research president-elect for 2022-2023.

In the second installment of a three-part video series, Heather Stefanski, MD, PhD, discusses the potential role of umbilical cord blood as a stem cell source.

Younger patients who developed treatment-related hemophagocytic lymphohistiocytosis after tisagenlecleucel infusion for relapsed or refractory B-cell acute lymphoblastic leukemia had significantly poorer outcomes, according to study results.

The FDA granted regenerative medicine advanced therapy designation to obecabatagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Fludarabine exposure appeared associated with improved clinical outcomes among pediatric patients undergoing chimeric antigen receptor T-cell therapy for refractory or relapsed B-cell acute lymphoblastic leukemia, study results showed.

SALT LAKE CITY — Zanubrutinib improved outcomes compared with bendamustine/rituximab among adults with treatment-naive deletion 17p-negative chronic lymphocytic leukemia or small lymphocytic lymphoma, according to phase 3 study results.